GUARD DURING ISCHEMIA AGAINST NECROSIS (GUARDIAN)
GUARD DURING ISCHEMIA AGAINST NECROSIS (GUARDIAN)
批准号:
6264461
负责人:
THOMAS VROBEL
金额:
$1.92万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The GUARDIAN Trial is a double-blind, placebo controlled multinational trial to investigate the effects of a NA+/H+ exchange inhibitor (cariporide), (HOE 642) on patient mortality and myocardial infarction in patients who are at risk of myocardial damage due to coronary artery disease. The primary purpose of the study is to investigate whether cariporide can reduce the incidence of death and myocardial infarction in patients who are at risk of myocardial damage during a coronary interventional procedure or coronary artery bypass graft surgery. Additionally, the safety and tolerability of this new drug will be evaluated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SIBRAFIBAN VS ASPIRIN PROTECTION FROM ISCHEMIC HEART EVENTS
-
批准号:6264452
-
项目类别:
-
资助金额:$1.92万
-
财政年份:1998
-
负责人:THOMAS VROBEL
-
依托单位:
SIBRAFIBAN VS ASPIRIN PROTECTION FROM ISCHEMIC HEART EVENTS
-
批准号:6305392
-
项目类别:
-
资助金额:$1.92万
-
财政年份:--
-
负责人:THOMAS VROBEL
-
依托单位:
GUARD DURING ISCHEMIA AGAINST NECROSIS (GUARDIAN)
-
批准号:6305401
-
项目类别:
-
资助金额:$1.92万
-
财政年份:--
-
负责人:THOMAS VROBEL
-
依托单位:
海外基金